PerkinElmer, Inc. (NYSE: PKI) Receives Emergency Authorization From FDA For Coronavirus Test

PerkinElmer, Inc. (NYSE: PKI) is now able to strengthen its position in the global infections diagnostics market. Coronavirus has spread all over the globe and demand for testing kits increases and is a global challenge now. FDA has provided PKI with the Emergency Utilization Authorization (EUA) for its New coronavirus RT-PCR test.

Laboratories that are under CLA certification can use this test kit to detect Coronavirus. The testing kits are now available in 30 different countries and are known with the name of in-vitro diagnostic device.

Coronavirus, officially known as COVID-19, which was started from Wuhan the city of China in December. The virus has spread all across the world with a total of 436,481 confirmed cases and almost 1,643 deaths were recorded around the world.

The testing kits which detect the novel coronavirus are in high demand. PKI new coronavirus Nucleic Acid testing kits is a real-time RT-PCR. These kits are used to detects the nucleic acid from COVID-19 in human’s nasopharynx and oropharynx specimens.

PerkinElmer shares went up 1% after an hour, following a 9.5% increase and end at $74.31 during the last trading session. PKI has an average volume of roughly 1.07 million compared to its trading volume of roughly 859,618. The total market capitalization of the company is $8.27 billion. PKI has a total dividend yield is 0.41%. The company’s 52-week low range of $62.91 and 52-week high range of $103.

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company is operating in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.

The Diagnostics segment offers instruments, reagents, and software products for the early detection of genetic disorders as well as infectious disease testing in the diagnostics market. PerkinElmer, Inc. was founded in 1973 and the company headquarter is in Waltham, Massachusetts.